All In Biotech

Drug Trial Radar · NCT06952699

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants With Narcolepsy Without Cataplexy (NT2)

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

May 6, 2025

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
May 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Narcolepsy without cataplexy or Narcolepsy Type 2 (NT2) is a lifelong condition that makes people very sleepy during the day, regardless of how much sleep they get at night. People with NT2 may fall asleep suddenly, have trouble staying awake during the day, or may not be able to sleep well at night. They may have difficulty thinking clearly, paying attention, or remembering things, during the day. These symptoms can make daily activities like driving, working, or caring for their families challenging, impacting their quality of life. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake. The main aim of this study is to learn how safe TAK-360 is and how well adults with NT2 tolerate it. Researchers also want to find out if TAK-360 can help people with NT2 stay awake and determine the right dosage needed to do that. Participants will be randomly (by chance, like drawing names from a hat) assigned to get either TAK-360 or placebo in the treatment period. The placebo is a pill that looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.

Conditions

  • Narcolepsy Type 2

Interventions

  • TAK-360Drug

    TAK-360 tablet.

  • PlaceboOther

    TAK-360 matching placebo tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)Time frame: Up to 15 Weeks

Locations

52 sites in 7 countries. Site status is shown where the registry gives one.

  • Takeda Site 36

    Auburn, Alabama · Active not recruiting

  • Takeda Site 39

    Chandler, Arizona · Withdrawn

  • Takeda Site 40

    Chula Vista, California · Recruiting

  • Takeda Site 14

    Redwood City, California · Recruiting

  • Takeda Site 10

    Santa Ana, California · Recruiting

  • Takeda Site 1

    Colorado Springs, Colorado · Recruiting

  • Takeda Site 48

    Bradenton, Florida · Recruiting

  • Takeda Site 13

    Brandon, Florida · Recruiting

  • Takeda Site 46

    Jacksonville, Florida · Recruiting

  • Takeda Site 44

    Miami, Florida · Recruiting

  • Takeda Site 35

    Miami, Florida · Recruiting

  • Takeda Site 3

    Orlando, Florida · Recruiting

  • Takeda Site 33

    Orlando, Florida · Active not recruiting

  • Takeda Site 32

    Atlanta, Georgia · Recruiting

  • Takeda Site 49

    Bowie, Maryland · Recruiting

  • Takeda Site 50

    Lansing, Michigan · Recruiting

  • Takeda Site 34

    Lathrup Village, Michigan · Recruiting

  • Takeda Site 4

    St Louis, Missouri · Recruiting

  • Takeda Site 37

    Middletown, New Jersey · Recruiting

  • Takeda Site 8

    Denver, North Carolina · Recruiting

  • Takeda Site 6

    Huntersville, North Carolina · Recruiting

  • Takeda Site 41

    Winston-Salem, North Carolina · Recruiting

  • Takeda Site 5

    Cincinnati, Ohio · Recruiting

  • Takeda Site 45

    Cleveland, Ohio · Recruiting

  • Takeda Site 2

    Columbia, South Carolina · Recruiting

  • Takeda Site 38

    Austin, Texas · Recruiting

  • Takeda Site 43

    Dallas, Texas · Withdrawn

  • Takeda Site 42

    El Paso, Texas · Completed

  • Takeda Site 47

    Mansfield, Texas · Withdrawn

  • Takeda Site 7

    San Antonio, Texas · Recruiting

  • Takeda Site 11

    Norfolk, Virginia · Recruiting

  • Takeda Site 28

    Beijing, Beijing Municipality, China · Recruiting

  • Takeda Site 29

    Guangzhou, Guangzhou, China · Recruiting

  • Takeda Site 51

    Changchun, Jilin, China · Recruiting

  • Takeda Site 27

    Shanghai, Shanghai Municipality, China · Recruiting

  • Takeda Site 15

    Paris, France · Recruiting

  • Takeda Site 17

    Montpellier, Hérault, France · Withdrawn

  • Takeda Site 23

    Bologna, Italy · Recruiting

  • Takeda Site 22

    Rome, Lazio, Italy · Recruiting

  • Takeda Site 31

    Verona, Veneto, Italy · Recruiting

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.